Oncoheroes Biosciences, member of CataloniaBio & HealthTech, announce a significant milestone in its mission to combat pediatric brain cancer. In a recent paper published in SLAS Discovery journal titled "Development of a High-Throughput Screening Platform to Identify New Therapeutic Agents for Medulloblastoma Group 3" authored by Inés Fallon, Henar Hernando, Olga Almacellas-Rabaiget, Berta Marti-Fuster, Cesare Spadoni, Darell D Bigner, and Eva Méndez, their team reveals the development of an innovative screening platform aimed at identifying potential drug candidates for medulloblastoma, a type of brain cancer prevalent in children.
Medulloblastoma presents a formidable challenge in oncology due to its resistance to traditional treatments. Oncoheroes recognize that early selection of compounds that effectively target cancer cells while sparing normal tissues is crucial for success in clinical trials. Addressing this challenge head-on, they have engineered a screening platform designed to minimize toxicity risks and advance molecules with the highest likelihood of efficacy and safety for patients.
Cesare Spadoni, Oncoheroes Chief Operating Officer and co-founder elaborates, "The development of this platform signifies a pivotal step forward in our quest to accelerate pediatric oncology drug development. By prioritizing safety and efficacy, we aim to accelerate the translation of scientific discoveries into life-saving therapies".
Comments